Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:BGMOTCMKTS:CLXPFOTCMKTS:CYDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.56-1.4%$4.10$3.21▼$8.06$863.71M0.594.53 million shs3.48 million shsBGMBGM Group$13.07+0.8%$12.37$5.26▼$17.17$1.26B1.3832,246 shs235,702 shsCLXPFCybin$7.90+2.5%$7.44$0.49▼$3.38$1.17BN/A551,962 shs213,319 shsCYDYCytoDyn$0.31-2.8%$0.32$0.10▼$0.49$398.30M1.291.30 million shs1.16 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%-2.96%-13.64%-29.63%-39.33%BGMBGM Group0.00%-16.91%+4.94%+18.02%+1,296,999,900.00%CLXPFCybin+2.46%-9.30%+5.33%+7.19%+2,804.41%CYDYCytoDyn0.00%-11.39%-19.06%+40.63%+135.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.0718 of 5 stars3.51.00.04.42.72.50.6BGMBGM GroupN/AN/AN/AN/AN/AN/AN/AN/ACLXPFCybinN/AN/AN/AN/AN/AN/AN/AN/ACYDYCytoDyn0.0371 of 5 stars0.02.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89205.87% UpsideBGMBGM Group 0.00N/AN/AN/ACLXPFCybin 0.00N/AN/AN/ACYDYCytoDyn 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYDY, ARDX, BGM, and CLXPF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M2.55N/AN/A$0.73 per share4.88BGMBGM Group$25.10M50.62N/AN/A$7.34 per share1.78CLXPFCybin$680K1,726.36N/AN/A$0.44 per share17.95CYDYCytoDynN/AN/AN/AN/A($0.11) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A11.48N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)BGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACLXPFCybin-$24.42M-$0.24N/AN/AN/AN/AN/AN/AN/ACYDYCytoDyn-$49.84M-$0.01N/A∞N/AN/AN/A-33.26%8/14/2025 (Estimated)Latest CYDY, ARDX, BGM, and CLXPF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ABGMBGM GroupN/AN/AN/AN/AN/ACLXPFCybinN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81BGMBGM GroupN/A3.392.82CLXPFCybinN/A13.5713.57CYDYCytoDynN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%BGMBGM GroupN/ACLXPFCybin0.01%CYDYCytoDyn5.06%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%BGMBGM Group58.66%CLXPFCybinN/ACYDYCytoDyn0.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableBGMBGM Group29897.22 million40.19 millionN/ACLXPFCybin50148.60 millionN/ANot OptionableCYDYCytoDyn201.25 billion1.24 billionNot OptionableCYDY, ARDX, BGM, and CLXPF HeadlinesRecent News About These CompaniesCytoDyn (OTCMKTS:CYDY) Shares Down 2.3% - Here's What HappenedJune 2, 2025 | marketbeat.comCytoDyn Announces New Data Suggesting Novel Mechanism Of Action Of Leronlimab In Solid TumorsMay 15, 2025 | nasdaq.comCytoDyn Releases ESMO Breast Cancer Meeting PosterMay 15, 2025 | globenewswire.comCytoDyn's new data shows leronlimab could treat solid tumorsMay 13, 2025 | msn.comCytoDyn highlights potential of lead drug against solid tumors with new dataMay 13, 2025 | seekingalpha.comCytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid TumorsMay 13, 2025 | globenewswire.comCytoDyn Inc.: CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial OfficerMay 6, 2025 | finanznachrichten.deCytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial OfficerMay 6, 2025 | globenewswire.comCytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, GermanyApril 29, 2025 | globenewswire.comCytoDyn Inc (296.SG)March 27, 2025 | finance.yahoo.comCytoDyn CEO writes March 2025 letter to shareholdersMarch 18, 2025 | markets.businessinsider.comCytoDyn Inc.: March 2025 Letter to ShareholdersMarch 18, 2025 | finanznachrichten.deMarch 2025 Letter to ShareholdersMarch 18, 2025 | globenewswire.comCytoDyn announces survival observations in mTNBC patientsFebruary 25, 2025 | markets.businessinsider.comCytoDyn Inc.: CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFebruary 24, 2025 | finanznachrichten.deMicro Cap Surging On Company Developed CCR5 Antagonist Showing Promise In PatientsFebruary 24, 2025 | msn.comCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFebruary 24, 2025 | globenewswire.comCytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | finanznachrichten.deCytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | finanznachrichten.deCytoDyn announces results from preclinical studies with SMCFebruary 6, 2025 | markets.businessinsider.comCytoDyn announces results from preclinical studies with SMCFebruary 6, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYDY, ARDX, BGM, and CLXPF Company DescriptionsArdelyx NASDAQ:ARDX$3.56 -0.05 (-1.39%) Closing price 04:00 PM EasternExtended Trading$3.59 +0.03 (+0.87%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.BGM Group NASDAQ:BGM$13.07 +0.10 (+0.77%) Closing price 04:00 PM EasternExtended Trading$13.02 -0.05 (-0.42%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Cybin OTCMKTS:CLXPF$7.90 +0.19 (+2.46%) As of 06/18/2025Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.CytoDyn OTCMKTS:CYDY$0.31 -0.01 (-2.79%) As of 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
